June 11, 2026

CELASC 2026 presentation: Impact of topical lidocaine-prilocaine analgesia on pain-induced grooming after ear notching of mice

CELASC 2026 presentation: Impact of topical lidocaine-prilocaine analgesia on pain-induced grooming after ear notching of mice

Finnish animal welfare legislation (Government Decree 1165/2023) effective as of January 1, 2024, requires establishments to apply “appropriate pain relief” in association with ear notching identification method of laboratory rodents(1). However, there is a lack of scientific evidence whether the benefits of applying analgesia outweigh the additional stress related to handling and drug administration. Our study aimed to determine if acute pain potentially linked to ear notching increases self-grooming behavior of the affected body area and if topical application of lidocaine-prilocaine ointment has the potential to mitigate such pain.

Materials and methods

A total of 103 group-housed, 12 – 19 weeks old male and female C57BL/6JRj mice were randomized to the following 4 groups (n = 25 – 26): 1, topical analgesic ointment + ear notch, 2, topical analgesic ointment + handling, 3, vehicle ointment + ear notch, 4, vehicle ointment + handling. Treatments were applied 30-60 minutes prior notching or handling only, then at specific timepoints (30, 60, 120, 240, 360 minutes and 24, 48, 72 hours) we utilized the Grooming Transfer Test(2) under ultraviolet-A light conditions with fluorescent oil applied to the ear during notching and associated handling or handling only, to score the grooming behavior of the animals by a blinded observer. 

Results

According to preliminary data, mice treated with analgesic ointment showed significantly higher Grooming Transfer Test scores at 240- and 360-minute timepoints (Fisher’s exact test: P=0.0214, and P=0.0017, respectively, n=25 – 26 animals/group) compared to groups receiving vehicle ointment (n=26 animals/group). 

Conclusions

The increase in self-grooming behavior in analgesic-treated groups suggests a pharmacological effect of the treatment, possibly the offset of the topical analgesic, given that all animals received analgesic or vehicle topical treatment. The data provides valuable insight into potentially refining rodent care in the scope of new legislation. 

References

  1. Valtioneuvoston asetus eläimille tehtävistä toimenpiteistä ja keinollisen lisäämisen menetelmistä (1165/2023), Section 3(13) [Government Decree on procedures performed on animals and methods of artificial reproduction]. Available from: www.finlex.fi 
  2. Oliver, V. L., Thurston, S. E., & Lofgren, J. L. Using Cageside Measures to Evaluate Analgesic Efficacy in Mice (Mus musculus) after Surgery. J Am Assoc Lab Anim Sci. 2018;57(2):186-201. PMCID: PMC5868385

Authors

Hajnalka Nádai, Anni Tenhunen, Sanna Tikka, Anna Mari Koponen, Päivi Partanen, Hanna-Marja Voipio

Our latest News

discover more
BioMed X and Boehringer Ingelheim Expand XSeed Labs to Advance Next-Generation Eye Therapies

BioMed X and Boehringer Ingelheim Expand XSeed Labs to Advance Next-Generation Eye Therapies

Ridgefield, CT, USA, July 9, 2026 – BioMed X, a leading innovation engine for pharma, and Boehringer Ingelheim today announced the launch of a new research team at XSeed Labs, the established innovation incubator embedded within Boehringer’s U.S. R&D headquarters in Ridgefield, Connecticut. The newly established research team, Team NIB (New Platform for Next-Generation Intraocular […]

Clinical Trial on Mild Stroke: Inpatient or Outpatient Treatment?

Clinical Trial on Mild Stroke: Inpatient or Outpatient Treatment?

Researchers at Heidelberg University’s Faculty of Medicine are investigating a new care model for older adults with mild strokes at the Heidelberg University Hospital’s Department of Neurology. The Joint Federal Committee (G-BA) is funding the ARTIFICE study with approximately 2.4 million euros. Full Text in German below. Klinische Studie zu leichtem Schlaganfall: stationär oder ambulant […]

VERAXA Biotech to Launch AI-enabled Drug Discovery Collaboration with Ardigen to Support Growing BiTAC® Pipeline

VERAXA Biotech to Launch AI-enabled Drug Discovery Collaboration with Ardigen to Support Growing BiTAC® Pipeline

Ardigen platform supports VERAXA’s in-house AI capabilities to optimize cancer target pair selection for conditionally active t cell engagers (TCEs) and antibody drug conjugates (ADCs) ZURICH, SWITZERLAND – July 13, 2026 — VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in designing novel cancer therapies, today announced a collaboration with Ardigen S.A., an AI-driven computational partner for modern […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp